Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T13:36:08.026Z.
Calculation as of: 2026-10-06T13:36:08.026Z.
Quote observation: 2026-10-06T13:35:08.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8c517f571e23d8c9640577b72a0d01a1674ca2fb527f0620093024032568825b
PE RATIO
N/A
Market Cap
$5.29B
PE Ratio
36.59
TTM Avg
36.67
3Y Avg
43.17
5Y Avg
53.01
Market Cap
$4.89B
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cogent Biosciences, Inc. (COGT) | $5.28B | N/A | N/A | N/A | N/A |
| Scholar Rock Holding Corporation (SRRK)vs › | $5.23B | N/A | N/A | N/A | N/A |
| Merit Medical Systems, Inc. (MMSI)vs › | $5.29B | 36.59 | 36.67 | 43.17 | 53.01 |
| Doximity, Inc. (DOCS)vs › | $5.40B | 33.95 | 29.46 | 43.55 | 46.11 |
| Erasca, Inc. (ERAS)vs › | $5.11B | N/A | N/A | N/A | N/A |
| BillionToOne, Inc. (BLLN)vs › | $5.08B | 177.99 | 879.32 | 879.32 | 879.32 |
| Dianthus Therapeutics, Inc. (DNTH)vs › | $4.93B | N/A | N/A | N/A | N/A |
| Adaptive Biotechnologies Corporation (ADPT)vs › | $4.89B | N/A | N/A | N/A | N/A |
| CRISPR Therapeutics AG (CRSP)vs › | $5.73B | N/A | 17.47 | 59.21 | 59.21 |
| Kiniksa Pharmaceuticals International, plc (KNSA)vs › | $5.82B | 77.88 | 136.52 | 215.24 | 141.48 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$30.93
Forward EPS (Est.)
$-2.21
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
